Form of Proxy

Approval of the Swiss management report, the consolidated financial statements and the statutory financial statements of the Company for the year ended December 31, 2025.

Approval of the appropriation of financial results.

Discharge of the members of the Board of Directors and the Executive Committee.

Re-election of Samarth Kulkarni, Ph.D., as member and Chairman

Re-election of Ali Behbahani, M.D.

Re-election of Maria Fardis, Ph.D.

Re-election of H. Edward Fleming, Jr., M.D.

Re-election of Simeon J. George, M.D.

Re-election of John T. Greene

Re-election of Katherine A. High, M.D.

Re-election of Sandesh Mahatme, LL.M.

Re-election of Briggs W. Morrison, M.D.

Re-election of Christian Rommel, Ph.D.

Re-election of Douglas A. Treco, Ph.D.

Re-election of the members of the Compensation Committee: Ali Behbahani, M.D.

Re-election of the members of the Compensation Committee: H. Edward Fleming, Jr., M.D

Re-election of the members of the Compensation Committee: John T. Greene

Re-election of the members of the Compensation Committee: Briggs W. Morrison, M.D.

Binding vote on maximum non-performance-related compensation for members of the Board of Directors from the 2026 Annual General Meeting to the 2027 annual general meeting of shareholders.

Binding vote on maximum equity for members of the Board of Directors from the 2026 Annual General Meeting to the 2027 annual general meeting of shareholders.

Binding vote on maximum non-performance-related compensation for members of the Executive Committee from July 1, 2026 to June 30, 2027.

Binding vote on maximum variable compensation for members of the Executive Committee for the current year ending December 31, 2026.

Binding vote on maximum equity for members of the Executive Committee from the 2026 Annual General Meeting to the 2027 annual general meeting of shareholders.

Non-binding advisory vote on the 2025 Compensation Report.

Non-binding advisory vote on the compensation paid to the Companys named executive officers under U.S. securities law requirements.

Approval of an increase to the Companys capital band.

Approval of an increase to the conditional share capital for the conversion of bonds and similar debt instruments.

Approval of the CRISPR Therapeutics AG 2026 Stock Option and Incentive Plan.

Re-election of the independent voting rights representative.

Re-election of the auditors.

Transact any other business that may properly come before the 2026 Annual General Meeting or any adjournment or postponement thereof.